2023 Top Story in Cardiology: It May Have Gone Unnoticed… A Commentary on the Recent FDA Approval of Empagliflozin for CKD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients With Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127.
- EMPA-KIDNEY Collaborative Group. Design, Recruitment, and Baseline Characteristics of the EMPA-KIDNEY Trial. Nephrol Dial Transplant. 2022;37(7):1317-1329.
- Laster M, Shen JI, Norris KC. Kidney Disease Among African Americans: A Population Perspective. Am J Kidney Dis. 2018;72(5 Suppl 1):S3-S7.
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of Chronic Kidney Disease in the United States. JAMA. 2007;298(17):2038-2047.
Disclosure statements are available on the authors' profiles: